Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1839100 for cough in idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
CTR20243858Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BI 1839100 in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), chronic cough, sponsored by Boehringer Ingelheim. Started Dec 2024; status: terminated.
02
Drugs
BI 1839100
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)chronic cough
Beyond the preview
Go deeper on CTR20243858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243858.